Early-stage biotech exits stealth mode with $5.3M funding boost

04/5/2013 | MedCityNews.com

Calif.-based Nurix has emerged from its stealth period with $5.3 million in equity funding from four investors, according to a securities filing. The biotech startup seeks to develop T-cell-specific immunosuppressant drugs for autoimmune diseases.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX